Longeveron (LGVN) Change in Acquisitions & Divestments (2023 - 2024)

Longeveron's (LGVN) quarterly Change in Acquisitions & Divestments came in at $2000.0 in Q3 2024, down 99.95% year-on-year from $3.9 million in Q4 2023, and down 99.31% quarter-over-quarter from $289000.0 in Q2 2024.

Longeveron (LGVN) Change in Acquisitions & Divestments (2023 - 2024) Analysis & Trends

Longeveron's Change in Acquisitions & Divestments history runs 2 years deep, the most recent figure standing at $2000.0 for Q3 2024.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 99.95% year-over-year to $2000.0 in Q3 2024; TTM through Dec 2024 was $352000.0, a 96.04% decrease from a year earlier, with the FY2024 full-year figure at $352000.0, down 96.04% from the prior year.
  • Change in Acquisitions & Divestments eased to $2000.0 in Q3 2024 per LGVN's latest filing, from $289000.0 in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $3.9 million in Q3 2023 and bottomed at $2000.0 in Q3 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Longeveron 15.18 Bn 15.16 Bn 264,000.00

Historic Data

Download Data
DateValue
Sep 30, 2024 2,000.00
Sep 30, 2024 2,000.00
Jun 30, 2024 289,000.00
Jun 30, 2024 289,000.00
Mar 31, 2024 61,000.00
Mar 31, 2024 61,000.00
Dec 31, 2023 1.82 Mn
Dec 31, 2023 1.82 Mn
Sep 30, 2023 3.94 Mn
Sep 30, 2023 3.94 Mn
Jun 30, 2023 2.66 Mn
Jun 30, 2023 2.66 Mn
Mar 31, 2023 461,000.00
Mar 31, 2023 461,000.00